Publications Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease Citation Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs. 2020 Dec;34(6):713-721. doi: 10.1007/s40259-020-00451-w. PMID: 33105016. Abstract The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn’s disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation. Tags Antibodies, Drug Therapy, IBD, Inflammatory Bowel Disease, Monoclonal, therapeutic use Read More
